PERSONALIZED CELL THERAPY MARKET ANALYSIS

Key Developments

• On March 14, 2024, Bristol Myers Squibb , Pharmaceutical company has announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T cell therapy. This approval is for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including specific inhibitors.
• In October 2023, Aurion Biotech, a clinical stage biotech company initiated a phase 1/2 clinical trial for AURN001, a novel cell therapy targeting corneal edema caused by corneal endothelial dysfunction. This therapy combines Y-27632, a Rho kinase inhibitor, with allogenic human corneal endothelial cells (neltependocel).
• In June 2023, Vertex Pharmaceuticals, BioPharmaceutical company Incorporated and Lonza announced a strategic collaboration to enhance manufacturing capabilities for Vertex's differentiated islet cell therapies aimed at producing insulin for individuals with type 1 diabetes. This partnership focuses on advancing the VX-264 and VX-880 programs, both currently in clinical trials.
• In May 2023, Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, entered into a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to jointly develop, manufacture, and commercialize advanced CAR T-cell therapies for the treatment of B-cell malignancies.